Henry J. Fuchs
2011
In 2011, Henry J. Fuchs earned a total compensation of $5.9M as Executive Vice President & Chief Medical Officer at BioMarin Pharmaceutical, a 240% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $169,040 |
|---|---|
| Option Awards | $1,088,640 |
| Salary | $440,768 |
| Stock Awards | $4,231,080 |
| Other | $4,940 |
| Total | $5,934,468 |
Fuchs received $4.2M in stock awards, accounting for 71% of the total pay in 2011.
Fuchs also received $169K in non-equity incentive plan, $1.1M in option awards, $440.8K in salary and $4.9K in other compensation.
Rankings
In 2011, Henry J. Fuchs' compensation ranked 837th out of 10,747 executives tracked by ExecPay. In other words, Fuchs earned more than 92.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 837 out of 10,747 | 92nd |
Division Manufacturing | 306 out of 3,960 | 92nd |
Major group Chemicals And Allied Products | 70 out of 1,033 | 93rd |
Industry group Drugs | 37 out of 781 | 95th |
Industry Pharmaceutical Preparations | 32 out of 571 | 94th |
Source: SEC filing on April 21, 2014.
Fuchs' colleagues
We found four more compensation records of executives who worked with Henry J. Fuchs at BioMarin Pharmaceutical in 2011.
2011
Jean-Jacques Bienaim
BioMarin Pharmaceutical
Chief Executive Officer
2011
Stephen Aselage
BioMarin Pharmaceutical
Executive Vice President & Chief Business Officer
2011
Robert Baffi
BioMarin Pharmaceutical
Executive Vice President, Technical Operations
2011
Jeffrey Cooper
BioMarin Pharmaceutical
Chief Financial Officer
News
BioMarin Pharmaceutical CEO Jean-Jacques Bienaim's 2021 pay rises 1% to $18M
April 12, 2022
BioMarin Pharmaceutical CEO Jean-Jacques Bienaim's 2020 pay slips 2% to $18M
April 13, 2021
BioMarin Pharmaceutical CEO Jean-Jacques Bienaim's 2019 pay rises 18% to $18M
April 14, 2020
BioMarin Pharmaceutical CEO Jean-Jacques Bienaim's 2018 pay slips 2% to $16M
April 23, 2019